AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients
Completed
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1836
- Registration Number
- NCT00681759
- Locations
- 🇫🇷
Research Site, Paris, France
Retrospective Treatment Pattern Survey for the Patients With Hypertension and Stroke
Completed
- Conditions
- Hypertension
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00681707
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
Phase 1
Completed
- Conditions
- Adverse EventsPharmacokinetic
- Interventions
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00681395
- Locations
- 🇺🇸
Site Reference ID/Investigator# 8089, Orlando, Florida, United States
Schizophrenic Patients in Integrated Care
Phase 4
Terminated
- Conditions
- SchizophreniaSchizoaffective DisorderSchizophreniform Disorder
- Interventions
- Drug: Quetiapine XROther: Integrated Care Program (ICP)
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT00681629
- Locations
- 🇩🇪
Research Site, Stolberg, Germany
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00681967
- Locations
- 🇨🇭
Research Site, Bern, Switzerland
Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 142
- Registration Number
- NCT00681382
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 217
- Registration Number
- NCT00681369
Quetiapine in Postpartum Depression
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT00681668
- Locations
- 🇩🇪
Research Site, Herten, Westfalen-Lippe, Germany
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00681746
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
AZD6280 Multiple Ascending Dose Study
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: AZD6280
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00681317
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath